Vol. 43 (6): 1167-1175, November – December, 2017
Osman Ergün 1, Pınar Aslan Koşar 2, İbrahim Onaran 2, Hakan Darıcı 3, Alim Koşar 4
1 Department of Urology, Konya Training and Research Hospital, Konya, Turkey; 2 Department of Medical Biology and Genetic, Süleyman Demirel University, Isparta, Turkey; 3 Deparment of Histology and Embryology, Süleyman Demirel University, Isparta, Turkey; 4 Department of Urology, Süleyman Demirel University, Isparta, Turkey
Objectives: To compare the effects and histopathological changes of botulinum neurotoxin type A and lysozyme gene injections into prostate tissue within a testosterone induced benign prostate hyperplasia rat model.
Materials and Methods: 40 male Wistar rats were randomized into four Groups. Group-1: Control, Group-2: Testosterone replacement, Group-3: Testosterone+botulinum neurotoxin type A, Group-4: Testosterone+plazmid DNA/liposome complex.
Results: Estimated prostate volume of the testosterone injected Groups were higher than the control (p <0.05). Actual prostate weight of the testosterone injected Groups was higher than the control Group (p <0.05). Testosterone undecanoate increased the prostate weight by 39%. Botulinum neurotoxin type A treatment led to an estimated prostate volume and actual prostate weights decreased up to 32.5% in rats leading to prostate apoptosis. Lysozyme gene treatment led to an estimated prostate volume and actual prostate weights decrease up to 38.7%.
Conclusion: Lysozyme gene and botulinum neurotoxin type A treatments for prostate volume decreasing effect have been verified in the present study that could be anew modality of treatment in prostatic benign hyperplasia that needs to be verified in large randomized human experimental studies.
Keywords: Prostatic Hyperplasia; Botulinum Toxins; Testosterone